Skip to main content

Table 4 Patients characteristics associated with acceptance in Prep users (N = 100)

From: Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users

Variable

Would accept injectionsa

(N = 89)

Would not accept injections

(N = 11)

P

Median age (IQR), years

38 (31–45)

41 (37–46)

0.21

Family life: single, n (%)

71 (80)

10 (91)

0.69

Has children, n (%)

4 (4)

0 (0)

 > 0.99

Worker, n (%)

80 (90)

10 (91)

 > 0.99

Travels, n (%)

  

0.78

 1–2/year

20 (22)

3 (27)

 

 > 2/year

67 (75)

8 (73)

 

 Never

2 (2)

0 (0)

 

Current smokers, n (%)

22 (25)

1 (9)

0.45

Alcohol consumption: yes, n (%)

78 (88)

9 (82)

0.63

Drugs consumption: yes n (%)

44 (49)

4 (36)

0.53

IV drugs consumption, n (%)

8 (9)

0 (0)

 > 0.99

Associative implication, n (%)

4 (4)

0 (0)

 > 0.99

Hypertension, n (%)

7 (8)

1 (9)

 > 0.99

Treated hypertension, n (%)

4 (4)

1 (9)

0.45

Diabetes, n (%)

4 (4)

0 (0)

 > 0.99

Treated diabetes, no. (%)

2 (2)

0 (0)

 > 0.99

Hypercholesterolemia, n (%)

1 (1)

1 (9)

0.21

Treated hypercholesterolemia, no. (%)

1 (1)

1 (9)

0.21

Psychiatric disorder, n (%)

15 (17)

2 (18)

 > 0.99

Antidepressant, n (%)

4 (4)

1 (9)

0.45

Other disease/condition, no. (%)

12 (13)

3 (27)

0.36

Taking any non-PrEP treatment, n (%)

10 (11)

3 (27)

0.15

Experience with injectable treatment, n (%)

50 (56)

6 (55)

 > 0.99

Partner aware of treatment, n (%)

80 (90)

11 (100)

0.59

Family aware of treatment, n (%)

21 (24)

3 (27)

0.72

Friends aware of treatment, n (%)

64 (72)

10 (91)

0.28

Never experienced AEs, n (%)

53 (60)

5 (45)

0.52

Never forgets treatment, n (%)

61 (69)

8 (73)

 > 0.99

Median no. partners in the last 3 months (IQR)

12.0 (6–21)

10.0 (5–17)

0.43

  1. aP-values were obtained by Wilcoxon or Fisher’s exact tests